Summary for Lutetium Lu177 Dotatate


BreastfeedingPediatric
  • Trade Name: Lutathera
  • Indications: Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (with octreotide)
  • Class: Radiopharmaceutical, Somatostatin analog
  • Half-life: 7 days
  • FDA Approval Date: 01/26/2018
  • Clinically important, potentially hazardous interactions with:
    None known
  • Pregnancy: Can cause fetal harm

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Symbol key

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top